In the Fall of 2015, The Wall Street Journal ran an article on its front page which effectively set the biotechnology world and the insular Silicon Valley scene on fire.
To stain the reputation of Elizabeth Holmes and her company, valued at $10 billion, was to alig.
To most people, the article amounted to nothing short of blasphemy.
Theranos, a much hailed startup which was disrupting the world of healthcare and led by a visionary young woman, was a fraud, the story claimed.
In the Fall of 2015, The Wall Street Journal ran an article on its front page which effectively set the biotechnology world and the insular Silicon Valley scene on fire